News >

CDK4/6 Inhibitors Carry Consistent Benefit Across HR+/HER2- Breast Cancer Settings

Caroline Seymour
Published: Wednesday, Feb 27, 2019

Joseph F. Stilwill, MD

Joseph F. Stilwill, MD

All 3 FDA-approved CDK4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)—show a consistent progression-free survival (PFS) advantage for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer, irrespective of endocrine therapy use, line of therapy, menopausal status, and clinical and pathologic features.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication